Medicenna in the spotlight (part X)

Deep-dive on new data update

Medicenna (MDNA) confirmed the partial response (PR) that the Company previously reported from their imaging scan in July. The patient with the confirmed PR was a 4th-line metastatic pancreatic cancer patient who had previously failed chemotherapy and checkpoint inhibitor therapy. They were in MDNA’s cohort 4 receiving 60 µg/kg dose.

In the first 4 cohor…